All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 4 points (0.0%) at 18,344 as of Wednesday, July 13, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,211 issues advancing vs. 1,725 declining with 124 unchanged.

The Health Care sector currently sits down 1.1% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the sector include Alibaba Group ( BABA), down 1.3%, Alexion Pharmaceuticals ( ALXN), down 1.3%, Shire ( SHPG), down 1.0%, Celgene ( CELG), down 0.8% and Abbott Laboratories ( ABT), down 0.7%. Top gainers within the sector include Teva Pharmaceutical Industries ( TEVA), up 4.3%, Valeant Pharmaceuticals International ( VRX), up 2.8%, Allergan ( AGN), up 2.0%, Mylan ( MYL), up 1.4% and CVS Health ( CVS), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Incyte ( INCY) is one of the companies pushing the Health Care sector lower today. As of noon trading, Incyte is down $1.47 (-1.7%) to $83.50 on light volume. Thus far, 283,386 shares of Incyte exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $83.07-$86.28 after having opened the day at $85.60 as compared to the previous trading day's close of $84.97.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Incyte Corporation focuses on the discovery, development, and commercialization of proprietary therapeutics in oncology. It offers JAKAFI for the treatment of myelofibrosis and polycythemia vera cancers. Incyte has a market cap of $16.1 billion and is part of the drugs industry. Shares are down 21.6% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Incyte a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Incyte as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, poor profit margins and generally higher debt management risk. Get the full Incyte Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $1.00 (-1.1%) to $88.63 on light volume. Thus far, 279,405 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $88.01-$90.41 after having opened the day at $90.30 as compared to the previous trading day's close of $89.63.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing medicines for serious diseases. Vertex Pharmaceuticals has a market cap of $22.0 billion and is part of the drugs industry. Shares are down 28.8% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself. Get the full Vertex Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Illumina ( ILMN) is down $3.64 (-2.4%) to $145.35 on light volume. Thus far, 423,705 shares of Illumina exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $145.07-$149.50 after having opened the day at $149.50 as compared to the previous trading day's close of $148.99.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Illumina, Inc. provides sequencing and array-based solutions for genetic analysis. The company's sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. Illumina has a market cap of $20.8 billion and is part of the drugs industry. Shares are down 22.4% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Illumina a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Illumina Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).